- Pharmaceutical companies
- Asia
- China
- Daiichi Sankyo Co., Ltd.
Daiichi Sankyo Co., Ltd. in China
Web: https://www.daiichisankyo.com.cn/
Addresses:
-
Guangzhou Office Unit
01-04, Floor 18, Tower 1, Xinghuan International Plaza, No. 13 Qiaoguang West Road, Yuexiu District, Guangzhou Tel
Phone: +86 20 8890 0181
Fax: +86 021-6039-7398
-
Daiichi Sankyo (China) Investment Co., Ltd.
51st Floor, Wheelock International Plaza, No. 1717 Nanjing West Road, Jing’an District, Shanghai
Phone: +86 21 6039 7200
Fax: + 86 021-6039-7398
-
Shanghai Office
BC, 19th Floor, Huaxin Haixin Building, No. 666 Fuzhou Road, Huangpu District, Shanghai
Phone: +86 21 6391 7891
Fax: +86 021-6391-7892
-
Daiichi Sankyo Pharmaceutical (Shanghai) Co., Ltd.
No. 500, Juli Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai
Phone: +86 21 6036 2000
Fax: +86 021-5080-46 41
-
Beijing Branch
Room 1608, Fosun International Center, No. 237 Chaoyang North Road, Chaoyang District, Beijing
Phone: +86 10 8534 7100
Fax: +86 010-8525-1085
-
Wuhan Office
Room 811, Block A, New World Center Office Building, No. 634 Jiefang Avenue, Hankou, Wuhan
Phone: +86 27 8377 7060
Fax: +86 027-8377-5130
Other Daiichi Sankyo Co., Ltd.'s locations around the world
Clinical Trials sponsored by Daiichi Sankyo Co., Ltd.
-
Daiichi Sankyo Co., Ltd.RekrutteringSolid svulst | Metastatisk solid svulst | Avansert kreftJapan, Forente stater, Canada
-
Daiichi Sankyo Co., Ltd.Aktiv, ikke rekrutterendeTenosynovial kjempecelletumorTaiwan, Kina
-
Daiichi Sankyo Co., Ltd.Daiichi SankyoAktiv, ikke rekrutterende
-
Daiichi Sankyo Co., Ltd.Daiichi SankyoAktiv, ikke rekrutterendeMelanomKorea, Republikken, Kina
-
Daiichi SankyoDaiichi Sankyo Co., Ltd.Aktiv, ikke rekrutterendeIkke-småcellet lungekreft Metastatisk | Ikke-småcellet lungekreft med mutasjon i epidermal vekstfaktorreseptorForente stater, Spania, Korea, Republikken, Frankrike, Storbritannia, Taiwan, Australia, Japan, Kina, Nederland, Italia, Tyskland, Østerrike, Belgia, Bulgaria, Singapore
-
Daiichi Sankyo Co., Ltd.Aktiv, ikke rekrutterendeVoksen T-celle leukemi/lymfomJapan
-
Daiichi SankyoDaiichi Sankyo Korea Co., Ltd.Aktiv, ikke rekrutterende
-
Daiichi SankyoAstraZeneca; Daiichi Sankyo Co., Ltd.Aktiv, ikke rekrutterendeBrystkreftKina, Forente stater, Spania, Ungarn, Israel, Korea, Republikken, Taiwan, Belgia, Østerrike, Den russiske føderasjonen, Sveits, Portugal, Frankrike, Canada, Italia, Storbritannia, Hellas, Japan, Tyskland, Sverige
-
Daiichi SankyoAstraZeneca; Daiichi Sankyo Co., Ltd.Aktiv, ikke rekrutterendeBrystkreftForente stater, Spania, Israel, Italia, Korea, Republikken, Belgia, Australia, Tsjekkia, Japan, Brasil, Frankrike, Storbritannia, Tyrkia, Hellas, Tyskland
-
Daiichi Sankyo Co., Ltd.FullførtMagekreftKorea, Republikken, Hong Kong, Taiwan, Kina
About Daiichi Sankyo Co., Ltd.
Daiichi Sankyo Company, Limited (Japanese: 第一三共株式会社, Hepburn: Daiichi Sankyō Kabushiki-gaisha) is a global pharmaceutical company and the second-largest pharmaceutical company in Japan. It achieved JPY 981.8 billion in revenue in 2019. The company owns the American biotechnology company Plexxikon, American pharmaceutical company American Regent, German biotechnology company U3 Pharma, and recently sold Ranbaxy Laboratories in India. Daiichi Sankyo Co., Ltd. is the producer of Benicar (Olmesartan), an angiotensin II receptor antagonist and top selling drug in the U.S. Global sales of Olmesartan in 2013 were 300.2 billion yen. Daiichi Sankyo, Inc. (DSI) began operating in the U.S. in 2006. It is the U.S. subsidiary of Daiichi Sankyo Company, Limited, and a member of the Daiichi Sankyo Group. The organization, which includes U.S. commercial operations and global clinical development (Daiichi Sankyo Pharma Development), is headquartered in Basking Ridge, New Jersey. Daiichi Sankyo Europe, GmbH (DSE), the European subsidiary, is headquartered in Munich, Germany. The organization is responsible for development and manufacturing for 12 European countries. Daiichi Sankyo Company, Limited is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).